-
Mashup Score: 0FDA panel to review renal denervation system PMA submissions - 11 month(s) ago
The FDA Circulatory System Devices Panel is set to review the PMA submissions for the ReCor and Medtronic renal denervation systems to treat patients with uncontrolled hypertension.
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0SCAI Drafts Guidance on Renal Denervation for Hypertension - 1 year(s) ago
The Society for Cardiovascular Angiography and Interventions releases draft guidance on the adoption of renal denervation for hypertension in anticipation of regulatory approval.
Source: MedscapeCategories: Cardiologists, Latest HeadlinesTweet-
RT @AnastasiaSMihai: Great to see👉 @SCAI Drafts Guidance on #RDN for #Hypertension https://t.co/lOdzfxNuCy Congrats all involved @AtulPa…
-
-
Mashup Score: 8Renal denervation - 1 year(s) ago
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Source: EuroInterventionCategories: Cardiologists, Latest HeadlinesTweet-
#SACIS_Studio #SACIS_Is_You Does your center offer #RDN❓ What are your criteria❓ Here’s⤵️ @ajaykirtane take on the topic Here’s the consensus document @EuroInterventio https://t.co/2xtWUmh2Oz And let’s also hear from the EIC of @PCRonline who will be joining this session… https://t.co/jSu1ALKj44
-
-
Mashup Score: 0How to Denervate With Current Renal Denervation Device Iterations - Cardiac Interventions Today - 1 year(s) ago
Drs. Brian Fulton, Jay Giri, Debbie Cohen, Herbert Aronow, & Taisei Kobayashi show how to denervate with current RDN device iterations, providing a step-by-step guide to RDN for the treatment of hypertension.
Source: Cardiac Interventions TodayCategories: Cardiologists, Latest HeadlinesTweet-
How to Denervate With Current Renal Denervation Device Iterations on @cardiacinterv https://t.co/F4fOeMWGg1 #RDN #HTN #ACCIC @SCAI @VMJ_SVM @HenryFordHealth @HFHCardioFellow
-
-
Mashup Score: 0
The SPYRAL HTN-ON MED renal denervation (RDN) trial failed to show that renal denervation was superior to sham control at improving ambulatory blood pressure (ABPM), but there was a modest improvement in office blood pressure. These were the key findings in the first six months of data of the full trial enrollment data presented as a late-breaking study at the American Heart Association (AHA)…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
SPYRAL HTN-ON MED renal denervation study did not meet primary endpoint #Cardiotwitter #Renaldenervation #RDN #hypertension #AHA22 https://t.co/aiQSGRZyql
-
-
Mashup Score: 0
Analysts said they have new questions about commercialization, reimbursement and physician acceptance for the Medtronic RDN program.
Source: Medical Design and OutsourcingCategories: Healthcare Professionals, Latest HeadlinesTweet-
What's next for @Medtronic #RDN after Symplicity Spyral trial 'surprise'? | #renaldenervation #hypertension https://t.co/I3tQno6sUq
-
-
Mashup Score: 1
Medtronic SYMPLICITY HTN-3 trial long-term results showed unexpected sustained blood pressure reductions The long-term results from the SYMPLICITY HTN-3 clinical trial were also presented at TCT. The study found patients who underwent radiofrequency renal denervation (RF RDN) with the first generation Medtronic Symplicity renal denervation system had a statistically significant reduction in…
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Renal denervation lowered blood pressure in two late-breaking TCT trials #TCT2022 #Cardiotwitter #TCT #hypertension #Renaldenervation #RDN https://t.co/4Myx8GzZho
-
-
Mashup Score: 1
This final report of the SYMPLICITY HTN-3 trial adds to the totality of evidence supporting the safety of renal artery denervation to 36 months after the procedure. From 12 months to 36 months after the procedure, patients who were originally randomly assigned to receive renal artery denervation had larger reductions in blood pressure and better blood pressure control compared with patients who…
Source: The LancetCategories: Cardiologists, Latest HeadlinesTweet-
Intriguing final 3yr follow-up results of the randomised SYMPLICITY HTN-3 Trial of #RDN in severe resistant HTN…especially in light of how much better current SPYRAL catheter performs in predictable denervation! #TCT2022 https://t.co/XlfdNHvpyJ
-
-
Mashup Score: 27
This final report of the SYMPLICITY HTN-3 trial adds to the totality of evidence supporting the safety of renal artery denervation to 36 months after the procedure. From 12 months to 36 months after the procedure, patients who were originally randomly assigned to receive renal artery denervation had larger reductions in blood pressure and better blood pressure control compared with patients who…
Source: The LancetCategories: Cardiologists, Latest HeadlinesTweet-
Great work by @DLBHATTMD et al who report long term of renal denervation with newer devices https://t.co/6LDG6ovAAt
-
Final Follow-up of #SYMPLICITYHTN3 by @DLBHATTMD now in @TheLancet simultaneous with #TCT2022 LBCT Enhanced efficacy in BP control with newer generation #RDN coupled with these long-term (>3-year) safety data bolster support of #RDN as a treatment option https://t.co/AZzdeOGltz https://t.co/81kAateeF8
-
-
Mashup Score: 8Renal denervation reduces atrial remodeling in hypertensive rats with metabolic syndrome - Basic Research in Cardiology - 2 year(s) ago
Atrial fibrillation (AF) is highly prevalent in hypertensive patients with metabolic syndrome and is related to inflammation and activation of the sympathoadrenergic system. The multi-ligand Receptor-for-Advanced-Glycation-End-products (RAGE) activates inflammation-associated tissue remodeling and is regulated by the sympathetic nervous system. Its counterpart, soluble RAGE (sRAGE), serves as…
Source: SpringerLinkCategories: Cardiologists, Latest HeadlinesTweet-
#EPeeps Renal denervation #RDN prevents #AFib in #MetS by reducing atrial sympathetic innervation/ modulating RAGE/sRAGE balance/ reducing pro-inflammatory & pro-fibrotic RAGE ligands @hohl_mathias @FelixMahfoud @VivekReddyMD đź“–https://t.co/fR8he7qcEj @SpringerNature @DGK_org https://t.co/7OXDimUqp3
-
The FDA Circulatory System Devices Panel is set to review the ReCor and Medtronic renal denervation systems in August #Cardiotwitter #Hypertension #renaldenervation #RDN #cardiology https://t.co/ZofKOGlp3b